Vaccination and Immunization

New CDC data show fewer kindergartners are fully vaccinated as exemption rates increased during the 2024-2025 school year.

Pediatricians are urged to follow 2024 guidelines amid ACIP upheaval, vaccine hesitancy, and access issues as children head back to school.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

This week, HHS Secretary Robert F. Kennedy Jr signed the ACIP's recommendation to remove the mercury-based preservative from all influenza vaccines.

A newly-published study identified specific groups of higher-risk children that could benefit most from monoclonal antibodies.

The final recommendation sign off decision will go to HHS secretary Robert F. Kennedy Jr.

The American Academy of Pediatrics will continue to hold its own childhood vaccine schedule, as it has since the 1930s.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on how PNPs can implement evidence-based strategies to encourage parents to vaccinate their children.

Currently, Vimkunya is FDA-approved for use among individuals aged 12 years and older.

The BLA for clesrovimab was based on results demonstrated in the phase 2b/3 CLEVER trial among healthy pre-term and full-term infants.

In this article, we recap a timeline of recent federal agency changes to routine COVID-19 vaccination intended for the pediatric population.

Federal health agencies have adjusted COVID vaccine guidance, potentially changing eligibility and access for pediatric patients. Experts respond in this article.

New phase 3b durability data revealed nirsevimab reduced RSV hospitalizations in infants by 82.7% through 180 days vs no intervention.

RFK Jr. stated he "couldn't be more pleased" to announce that COVID-19 vaccination among healthy children and pregnant women has been removed from CDC's immunization schedule.

A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments.

Tina Tan, MD, FIDSA, FPIDS, FAAP, comments on the FDA's recent selection of the 2025-2026 influenza vaccine compositions, without the CDC's ACIP meeting and FDA's VRBPAC meeting.

Mary Koslap-Petraco highlighted the need to address vaccine hesitancy, catch up on immunizations, and build trust with parents at the 2025 NAPNAP National Conference on Pediatric Health Care.

Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP, reacts to the recent cancelations of the ACIP and VRBPAC and comments on the potential down stream effects.

"The measles outbreak that is currently happening in Texas and New Mexico is occurring in an area of the states that have very high anti-vaccine sentiments," Tan said.

"Vaccines are our absolute best defense for protecting people of all ages against many serious infectious diseases," Tan said in a statement as president of IDSA.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, breaks down key highlights of the latest double issue of Contemporary Pediatrics.

Study findings underscore the effectiveness of a dual approach to RSV prevention.

Amin Barakat, MD, FAAP, details meningococcal disease vaccines and highlights the recently FDA-approved MenABCWY vaccine from GSK.

Nurse practitioner Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN offers her thoughts on the recent FDA approval of GSK's meningococcal ABCWY vaccine.

The combination vaccine targets 5 groups of the bacteria Neisseria meningitidis (A,B,C,W, AND Y) that cause the most invasive meningococcal disease cases (IMD) globally.